Plant-based oral vaccines: results of human trials

Curr Top Microbiol Immunol. 2009:332:103-17. doi: 10.1007/978-3-540-70868-1_6.

Abstract

Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Administration, Oral
  • Clinical Trials as Topic
  • Escherichia coli Vaccines / administration & dosage
  • Escherichia coli Vaccines / adverse effects
  • Escherichia coli Vaccines / biosynthesis
  • Escherichia coli Vaccines / immunology
  • Humans
  • Plants, Genetically Modified / genetics*
  • Plants, Genetically Modified / metabolism*
  • Solanum tuberosum / genetics
  • Solanum tuberosum / metabolism
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / adverse effects
  • Vaccines, Subunit / biosynthesis*
  • Vaccines, Subunit / immunology*
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / adverse effects
  • Viral Vaccines / biosynthesis
  • Viral Vaccines / immunology
  • Zea mays / genetics
  • Zea mays / metabolism

Substances

  • Escherichia coli Vaccines
  • Vaccines, Subunit
  • Viral Vaccines